Brainstorm Cell Therapeutics BCLI
OTC BCLI
$0.99 +0.07 (+7.61%)
At close: Nov 10, 2026 · 4:00 PM EST

Brainstorm Cell Therapeutics (BCLI) Cash from Discontinued Operations (2009 - 2010)

Updated

Analysis

Brainstorm Cell Therapeutics (BCLI) Cash from Discontinued Operations (2009 - 2010) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discont. Ops (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 6.56 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Brainstorm Cell Therapeutics 10.92 Mn 10.85 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2010 164,000.00
Mar 31, 2009 164,000.00
API Access

Brainstorm Cell Therapeutics Cash from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-discontinued-operations&ticker=BCLI&period=max&api_key=YOUR_API_KEY